FDA Approves Novel Glucose Monitoring System
The Food and Drug Administration yesterday approved the first continuous glucose monitoring system with a fully implantable sensor, designed to measure glucose levels in adults with diabetes for up to 90 days. Once implanted under the skin during an outpatient procedure, the sensor sends information to a mobile app to alert users if glucose levels are too high or too low. “The FDA is committed to advancing novel products that leverage digital technology to improve patient care,” said FDA Commissioner Scott Gottlieb, M.D.
Related News Articles
Headline
A bipartisan group of 60 senators April 2 reintroduced the CONNECT for Health Act, AHA-supported legislation that would expand patient access to telehealth…
Headline
Today the Drug Enforcement Administration and Department of Health and Human Services announced that the effective date for the final rule regarding…
Headline
The Department of Health and Human Services and Drug Enforcement Administration published a series of rules Jan. 15 related to telemedicine prescribing of…
Headline
The Department of Health and Human Services Health Sector Cybersecurity Coordination Center Jan. 8 released guidance on cybersecurity for telehealth…
Headline
The Drug Enforcement Administration and Department of Health and Human Services Nov. 15 issued a final rule extending certain telemedicine prescribing…
Headline
In comments Nov. 12 to majority and minority leaders of the House and Senate, the AHA requested that Congress act on key priorities for hospitals and health…